We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

Thu, 23rd Feb 2023 09:02

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

The FTSE 100 index opened down 13.51 points, or 0.2%, at 7,917.12. The FTSE 250 was up 172.45 points, 0.9%, at 19,852.74, and the AIM All-Share was up 3.13 points, 0.4%, at 855.41.

The Cboe UK 100 was down 0.2% at 792.14, the Cboe UK 250 was up 1.0% at 17,341.55, and the Cboe Small Companies was 0.1% lower at 13,929.97.

In European equities on Thursday, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was up 0.2%.

Investors were also considering the latest policy-meeting minutes from the US Federal Reserve.

Although the 25 basis point rate hike was agreed upon, the minutes showed a "few" members said they wanted a half-point, or 50-basis-point, hike that would show even greater resolve to get inflation down.

Since the February meeting, regional presidents James Bullard of St Louis and Loretta Mester of Cleveland have said they were among the group that wanted a more aggressive move at the January 31 to February 1 rate-setting meeting.

"A lot of the takeaway from the minutes last night was that they didn't provide a lot of new information. That isn't entirely true, given that we now know that a number of other Fed officials share the view of Bullard and Mester that more needs to be done, and in light of the data since then that position will only have hardened further," said CMC Markets' Michael Hewson.

There was a fairly muted response on Wall Street, with the Dow Jones Industrial Average ending down 0.3% and the S&P 500 down 0.2% but the Nasdaq Composite up 0.1%.

The dollar was stronger against major currencies.

Sterling was quoted at USD1.2052 early Thursday, lower than USD1.2066 at the London equities close on Wednesday. The euro traded at USD1.0612, down from USD1.0629. Against the yen, the dollar was quoted at JPY134.86, firm on JPY134.67.

In the FTSE 100, Rolls-Royce shares jumped 17% in early trade.

The jet engine maker's annual revenue increased to GBP13.52 billion from GBP11.22 billion a year before, but its pretax loss widened to GBP1.50 billion from GBP294 million, due to GBP2.42 billion in net financing costs. Operating profit improved to GBP837 million from GBP513 million, however.

CEO Tufan Erginbilgic said Rolls-Royce will begin a strategic review as part of its restructuring programme, and will share the findings and its medium term goals in the second half of 2023. Looking to 2023, the company noted a "continued recovery" in its end markets, and is confidence of higher profit and cash flow.

"When Erginbilgic took over earlier this year he didn't hold back in the challenges facing the current business. Likening the company to a 'burning platform' his words pulled the shares off their recent highs, which where their highest levels since February last year," said CMC's Hewson.

"The announcement of a strategic review of all the businesses should go some way to indicating how he intends to steer the company."

WPP added 3.9% in early trading, boasting strong performance across all its major agencies in 2022.

Ad agency said revenue in 2022 rose 13% to GBP14.43 billion from GBP12.80 billion in 2021. Revenue less pass-through costs rose 14% to GBP11.80 billion.

Pretax profit jumped 22% to GBP1.16 billion from GBP951 million. WPP raised its dividend to 39.4p from 31.2p.

"We enter 2023 in a strong financial position with good momentum from new business and the many opportunities ahead of us," said CEO Mark Read. WPP expects like-for-like revenue less pass-through costs growth of 3% to 5% in 2023.

"As a media giant, WPP has been stung by a global slowdown in marketing spending brought on my enormous geopolitical and economic stress. By all accounts this looks to be reversing, which has fed into strong growth at the end of the year," said Sophie Lund-Yates, lead equity analyst at Hargreaves Lansdown.

At the other end of London's blue-chips was Mondi, down 6.3%.

The packaging and paper company said revenue jumped 28% in 2022 to EUR8.90 billion from EUR6.97 billion a year before. Pretax profit more than doubled to EUR1.56 billion from EUR712 million. The figures are based on continuing operations, excluding its divested Russian operations.

Mondi recommended a dividend of 70 euro cents, up 7.7% from 65 cents a year before. However, investors seemed perturbed by the firm's shaky outlook.

"Whilst a number of input costs are starting to decline, we continue to see an environment of softer demand and pricing, with destocking expected to continue through the first quarter," Mondi warned.

Ex-dividend stocks also were holding back the FTSE 100. AstraZeneca was down 1.8%, Unilever 1.4%, and Barclays 0.6%.

In the FTSE 250, John Wood surged 31%.

Late Wednesday, the energy sector-focused engineering and consulting business said it has rebuffed three unsolicited proposals for a takeover by Apollo Global Management.

It said the most recent approach was received in late January, proposing a cash offer for all of its shares at a price of 230 pence each, around GBP1.59 billion in total.

John Wood said the board "carefully considered" each of the proposals with its financial advisers and "engaged on a limited basis" with Apollo, before unanimously rejecting each proposal.

Hikma Pharmaceuticals rose 5.3%, as it reported a dip in annual revenue while profit tumbled, but shared a more positive outlook for the current year.

Revenue edged down 1% to USD2.52 billion from USD2.55 billion, but pretax profit dropped to USD233 million from USD544 million.

This was due to an impairment in its Generics business. Hikma noted a strong performance from Injectables and Branded businesses, which helped to partially offset the Generics decline. The annual dividend was lifted by 4% to 56 cents.

"Looking ahead, we are confident that we will deliver good growth across all three of our businesses in 2023," said Chair & CEO Said Darwazah.

On AIM, Quadrise Fuels added 10%.

The residual oil technology licensor updated on its Moroccan material transfer & cooperation agreement. The company confirmed the MSAR fuel for the forthcoming trial has been cleared at Moroccan customers, and is now on its way to the client's facility.

It is now finalising the trial schedule with its client, and expects fuel trials to begin before the end of the current quarter.

In Asia on Thursday, financial markets in Tokyo were closed for the Emperor's Birthday holiday. In China, the Shanghai Composite fell 0.1%, while the Hang Seng index in Hong Kong lost 0.4%. The S&P/ASX 200 in Sydney closed down 0.4%.

Gold was quoted at USD1,827.78 an ounce early Thursday, down from USD1,835.00 on Wednesday. Brent oil was trading at USD80.96 a barrel, lower than USD81.16

Still to come on Thursday's economic calendar, there's a eurozone inflation reading at 1000 GMT, before the latest US jobless claims data at 1330 GMT.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.